- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02310724
TODAY2 Phase 2 Follow-up (T2P2)
29 juli 2021 uppdaterad av: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Long-term Post-Intervention Follow-up of the TODAY Cohort (Treatment Options for Type 2 Diabetes in Youth and Adolescents)
The primary objective of T2P2 is to track the progression of T2D and related comorbidities and complications in the TODAY cohort as they transition to young adulthood. We hypothesize that:
- Youth-onset type 2 diabetes (T2D) will progress rapidly and result in high rates of diabetes-related medical complications and comorbidities.
- The rapid rate of progression is related to increased insulin resistance characteristic of puberty, worse β-cell function, degree of glycemic control, control of non-glycemic factors, and obesity itself.
Studieöversikt
Studietyp
Observationell
Inskrivning (Faktisk)
517
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90027
- Children's Hospital Los Angeles
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- University of Colorado Denver Children's Hospital
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06520
- Yale University School of Medicine Department of Pediatrics
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Förenta staterna, 02215
- Joslin Diabetes Center
-
-
Missouri
-
Saint Louis, Missouri, Förenta staterna, 63110
- Washington University
-
Saint Louis, Missouri, Förenta staterna, 63104
- Saint Louis University
-
-
New York
-
New York, New York, Förenta staterna, 10032
- Columbia University Naomi Berrie Diabetes Center
-
Syracuse, New York, Förenta staterna, 13210
- SUNY Upstate New York University
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44106
- Case Western Reserve University Rainbow Babies and Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- University of Oklahoma Health Science Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Förenta staterna, 15224
- Children's Hospital of Pittsburgh
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Baylor College of Medicine
-
San Antonio, Texas, Förenta staterna, 78229
- University of Texas Health Sciences Center
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
15 år och äldre (Barn, Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Testmetod
Icke-sannolikhetsprov
Studera befolkning
All subjects randomized into the TODAY study are eligible to participate in T2P2.
There are no additional inclusion or exclusions criteria for participation in T2P2.
Beskrivning
Inclusion Criteria:
- Participated in TODAY clinical trial.
Exclusion Criteria:
-
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
TODAY cohort
All subjects randomized to the TODAY clinical trial are eligible to participate in T2P2.
The study performs long-term observation only and administers no treatment, care, or management.
|
This protocol is observation only and involves no intervention, care, treatment, or management.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
diabetic retinopathy
Tidsram: year 4
|
a microvascular complication determined by fundus photography
|
year 4
|
microalbuminuria
Tidsram: every 12 months
|
a microvascular complication determined by urine albumin excretion >= 30 mg/day
|
every 12 months
|
overt diabetic nephropathy
Tidsram: every 12 months
|
a microvascular complication determined by glomerular filtration rate < 70 mL/min/1.73m2
|
every 12 months
|
peripheral diabetic neuropathy
Tidsram: every 12 months
|
a microvascular complication defined as the presence of Michigan Neuropathy Screening Instrument (MNSI) exam score >2 and <8 out of 10 appropriate responses to the Semmes-Weinstein monofilament (SW-MF) in either foot.
|
every 12 months
|
cardiac function
Tidsram: year 2
|
a macrovascular (cardiovascular) risk indicator determined by echocardiogram
|
year 2
|
arterial stiffness
Tidsram: year 5
|
a macrovascular (cardiovascular) risk indicator determined by pulse wave velocity
|
year 5
|
cardiovascular risk lipid values
Tidsram: every 12 months
|
a macrovascular (cardiovascular) risk indicator determined by abnormal lipid value for LDL (>= 130 mg/dL) or triglycerides (>= 300 mg/dL)
|
every 12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
glycemic control
Tidsram: every 12 months
|
determined by HbA1c (annual)
|
every 12 months
|
psychological disorder
Tidsram: every 12 months
|
determined by scores on the following participant self-report standard surveys: (a) the Beck Depression Inventory II (BDI-II), (b) the Patient Health Questionnaire (PHQ) scales for somatic symptoms, anxiety, and alcohol use; participants are also interviewed about emotional or mental health problems involving referral, treatment, or hospitalization, and psychiatric diagnoses made by a non-study source that can be confirmed according to standard study criteria from acquired medical records are also recorded
|
every 12 months
|
body composition
Tidsram: every 12 months
|
determined by body mass index (BMI) computed from physical measurements of height and weight
|
every 12 months
|
insulin sensitivity and beta cell function
Tidsram: participant years 6 and 9 from baseline
|
determined by oral glucose tolerance test (at 6 and 9 years from randomization) to derive measures of insulin sensitivity (1/insulin0), insulin secretion (ΔC-peptide30-0/Δglucose30-0, Δinsulin30-0/Δglucose30-0 if not on insulin), and the oral disposition index (oDI = insulin sensitivity x insulin secretion)
|
participant years 6 and 9 from baseline
|
eating disorder
Tidsram: every 12 months
|
determined by score on participant self report questionnaire Eating Disorder Diagnostic Scale (EDDS)
|
every 12 months
|
health-related quality of life
Tidsram: every 12 months
|
determined by score on the participant self report questionnaire Pediatric Quality of Life Inventory version 4.0 with age-specific versions for teen (13-18), young adult (19-25), and adult (≥26)
|
every 12 months
|
blood pressure
Tidsram: every 12 months
|
determined by collection of blood pressure
|
every 12 months
|
sleep function
Tidsram: years 2-3
|
determined by scores on standard questionnaires and in-lab polysomnogram
|
years 2-3
|
life stress
Tidsram: every 12 months
|
determined by participant self report questionnaire based on the Yeaworth Adolescent Life Change Event Scale
|
every 12 months
|
healthcare usage
Tidsram: every 6 months
|
determined by participant self report about visits, referrals, treatments, tests, and procedures related to healthcare
|
every 6 months
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Utredare
- Huvudutredare: Sonia Caprio, MD, Yale University
- Huvudutredare: Silva Arslanian, MD, University of Pittsburgh
- Studiestol: Philip S Zeitler, MD PhD, University of Colorado Denver Children's Hospital
- Huvudutredare: Jeanie B Tryggestad, MD, University of Oklahoma Health Science Center
- Huvudutredare: Mitchell E Geffner, MD, Children's Hospital Los Angeles
- Huvudutredare: Robin S Goland, MD, Columbia University Naomi Berrie Diabetes Center
- Huvudutredare: Lorraine L Katz, MD, Children's Hospital of Philadelphia
- Huvudutredare: Lori MB Laffel, MD, Joslin Diabetes Center
- Huvudutredare: Jane L Lynch, MD, University of Texas Health Sciences Center at San Antonio
- Huvudutredare: Siripoom V McKay, MD, Baylor College of Medicine
- Huvudutredare: Rose Gubitosi-Klug, MD, Case Western Reserve University Rainbow Babies and Children's Hospital
- Huvudutredare: Sherida E Tollefsen, MD, St. Louis University
- Huvudutredare: Ruth S Weinstock, MD PhD, SUNY Upstate Medical Center
- Huvudutredare: Neil H White, MD, Washington University School of Medicine
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Allmänna publikationer
- Trief PM, Uschner D, Tung M, Marcus MD, Rayas M, MacLeish S, Farrell R, Keady J, Chao L, Weinstock RS. Diabetes Distress in Young Adults With Youth-Onset Type 2 Diabetes: TODAY2 Study Results. Diabetes Care. 2022 Mar 1;45(3):529-537. doi: 10.2337/dc21-1689.
- TODAY Study Group; Shah RD, Braffett BH, Tryggestad JB, Hughan KS, Dhaliwal R, Nadeau KJ, Levitt Katz LE, Gidding SS. Cardiovascular risk factor progression in adolescents and young adults with youth-onset type 2 diabetes. J Diabetes Complications. 2022 Mar;36(3):108123. doi: 10.1016/j.jdiacomp.2021.108123. Epub 2022 Jan 3.
- TODAY Study Group. Health Care Coverage and Glycemic Control in Young Adults With Youth-Onset Type 2 Diabetes: Results From the TODAY2 Study. Diabetes Care. 2020 Oct;43(10):2469-2477. doi: 10.2337/dc20-0760. Epub 2020 Aug 10.
- TODAY Study Group. Longitudinal Changes in Cardiac Structure and Function From Adolescence to Young Adulthood in Participants With Type 2 Diabetes Mellitus: The TODAY Follow-Up Study. Circ Heart Fail. 2020 Jun;13(6):e006685. doi: 10.1161/CIRCHEARTFAILURE.119.006685. Epub 2020 Jun 5.
- TODAY Study Group; Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, Tesfaldet B, Tryggestad J, White NH, Zeitler P. Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med. 2021 Jul 29;385(5):416-426. doi: 10.1056/NEJMoa2100165.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
1 mars 2014
Primärt slutförande (Faktisk)
17 januari 2020
Avslutad studie (Faktisk)
17 januari 2020
Studieregistreringsdatum
Först inskickad
18 juni 2014
Först inskickad som uppfyllde QC-kriterierna
4 december 2014
Första postat (Uppskatta)
8 december 2014
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
5 augusti 2021
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
29 juli 2021
Senast verifierad
1 juli 2021
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- DK61230-T2P2
- U01DK061230 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
JA
IPD-planbeskrivning
The TODAY/TODAY2 Study Group engages in a number of methods to disseminate and share resources.
- Findings are reported in manuscripts and presentations.
- An active Ancillary Studies Committee reviews proposals to access the study cohort, the central database, and stored biospecimens.
- Materials from the TODAY lifestyle intervention program and the standard diabetes education manual for adolescents developed by study experts are made available for public access on the website https://today.bsc.gwu.edu/web/today/home.
- The study group adheres to the policies of the NIDDK Central Repositories to make data available to other scientific investigators. A TODAY2 de-identified database will be prepared and transferred along with excess stored biospecimens. Appropriate informed consent is required to transfer stored biospecimens.
- TODAY establishes collaborative arrangements to work with other federally funded study groups.
Tidsram för IPD-delning
Data will be prepared and provided to the NIDDK Data Repository in early 2022
Kriterier för IPD Sharing Access
Currently with approval of the Ancillary Studies Committee and after 2022 as determined by the NIDDK Data Repository
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Diabetes typ 2
-
Jiangsu HengRui Medicine Co., Ltd.Avslutad
-
Bnai Zion Medical CenterOkänd
-
Mathias Ried-LarsenAvslutadDiabetes mellitus, typ 2 | Typ 2-diabetes mellitus | Diabetes typ 2 | Typ 2 diabetes mellitusDanmark
-
Shanghai HEP Pharmaceutical Co., Ltd.Indragen
-
Jeil Pharmaceutical Co., Ltd.Har inte rekryterat ännuTyp 2-diabetes mellitusKorea, Republiken av
-
Nanjing First Hospital, Nanjing Medical UniversityRekrytering
-
Sun Yat-sen UniversityThe First Affiliated Hospital with Nanjing Medical University; Guangdong... och andra samarbetspartnersAvslutad
-
BayerAktiv, inte rekryterande
-
Nanjing First Hospital, Nanjing Medical UniversityAktiv, inte rekryterandeTyp 2-diabetes mellitusKina
Kliniska prövningar på TODAY cohort
-
University of Alabama at BirminghamEunice Kennedy Shriver National Institute of Child Health and Human Development...Anmälan via inbjudanSexuellt överförbara sjukdomar | HivFörenta staterna
-
Abramson Cancer Center at Penn MedicineRekryteringAllogen transplantationFörenta staterna
-
Istituto Clinico HumanitasRekryteringKolorektal cancer | KirurgiItalien
-
Ferring PharmaceuticalsAvslutad
-
Clinical Research Centre, MalaysiaHospital Queen Elizabeth, MalaysiaAvslutadCovid19 | Kritiskt sjukMalaysia
-
Bristol-Myers SquibbCardioxyl Pharmaceuticals, IncAvslutadHjärtsviktFörenta staterna
-
Hospitales Universitarios Virgen del RocíoAndaluz Health ServiceAvslutad
-
Prana Biotechnology LimitedAvslutadFriska volontärerAustralien
-
Centre Oscar LambretInstitut National de la Santé Et de la Recherche Médicale, FranceRekryteringFast tumör, vuxenFrankrike
-
Syneos HealthSynerK Pharmatech (Suzhou) LimitedRekryteringFörhöjt lågdensitetslipoproteinkolesterolAustralien